{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:52:29Z","timestamp":1768521149783,"version":"3.49.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.prro.2023.05.007","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T06:28:55Z","timestamp":1686205735000},"page":"e515-e529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Achievable Dosimetric Constraints in Stereotactic Reirradiation for Recurrent Prostate Cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Manon","family":"Baty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khemara","family":"Gnep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolwenn","family":"Delaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lacornerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2023.05.007_bib0001","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.prro.2023.05.007_bib0002","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","article-title":"Anatomic patterns of recurrence following biochemical relapse in the dose-escalation era for prostate patients undergoing external beam radiotherapy","volume":"194","author":"Zumsteg","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0003","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2015.03.006","article-title":"Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled","volume":"115","author":"Huang","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0005","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.juro.2015.04.111","article-title":"Patterns of local failure following radiation therapy for prostate cancer","volume":"194","author":"Jalloh","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0006","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1464-410X.2012.11774.x","article-title":"Androgen deprivation therapy: Evidence-based management of side effects","volume":"111","author":"Ahmadi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.prro.2023.05.007_bib0007","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: A systematic review of the literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0008","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bju.13766","article-title":"Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients","volume":"119","author":"Crouzet","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.prro.2023.05.007_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2010.12.012","article-title":"Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer","volume":"60","author":"Williams","year":"2011","journal-title":"Eur Uro.l"},{"key":"10.1016\/j.prro.2023.05.007_bib0010","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00345-012-0982-2","article-title":"Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: Update from the COLD registry","volume":"31","author":"Spiess","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2012.07.008","article-title":"Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: Long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre","volume":"64","author":"Wenske","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0022-5347(01)65335-7","article-title":"Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: Results in 143 patients","volume":"157","author":"Cespedes","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.euf.2015.09.004","article-title":"Comparative oncologic and toxicity outcomes of salvage radical prostatectomy versus nonsurgical therapies for radiorecurrent prostate cancer: A meta\u2013regression analysis","volume":"2","author":"Philippou","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.prro.2023.05.007_bib0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.canrad.2019.07.125","article-title":"Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?","volume":"23","author":"Baty","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.prro.2023.05.007_bib0015","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.adro.2020.04.022","article-title":"A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: Systematic review and meta-analysis","volume":"5","author":"Corkum","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.05.007_bib0017","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijrobp.2016.05.024","article-title":"Reirradiation of prostate cancer local failures after previous curative radiation therapy: Long-term outcome and tolerance","volume":"96","author":"Zilli","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0018","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1:\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0019","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited \u2013 An analysis of clinical results from 14 168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The alpha\/beta ratio for prostate cancer: What is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0021","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0022","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): Patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0024","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.05.007_bib0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.canrad.2021.11.017","article-title":"External radiotherapy for prostatic cancers","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer\/Radioth\u00e9r"},{"key":"10.1016\/j.prro.2023.05.007_bib0026","unstructured":"NCCN. National Comprehensive Cancer Network Prostate cancer. Version 3.2020; Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_blocks.pdf. Accessed July 4, 2023."},{"key":"10.1016\/j.prro.2023.05.007_bib0027","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer","volume":"82","author":"Jereczek-Fossa","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150197","article-title":"Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer","volume":"88","author":"Zerini","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2023.05.007_bib0029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canrad.2016.03.005","article-title":"Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report","volume":"20","author":"Janoray","year":"2016","journal-title":"Cancer\/Radioth\u00e9r"},{"key":"10.1016\/j.prro.2023.05.007_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-017-0833-9","article-title":"Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: Preliminary results of the Oscar Lambret Center","volume":"12","author":"Leroy","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13014-017-0789-9","article-title":"Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy","volume":"12","author":"Mbeutcha","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0032","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2017.11.007","article-title":"Robotic stereotactic retreatment for biochemical control in previously irradiated patients affected by recurrent prostate cancer","volume":"30","author":"Loi","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1533033818785496","article-title":"Salvage CyberKnife-based reirradiation of patients with recurrent prostate cancer: The single-center experience","volume":"17","author":"Miszczyk","year":"2018","journal-title":"Technol Cancer Res Treat"},{"issue":"1094","key":"10.1016\/j.prro.2023.05.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180494","article-title":"Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)","volume":"92","author":"Jereczek-Fossa","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2023.05.007_bib0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: A retrospective multicenter study of the GETUG","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0036","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ijrobp.2019.02.041","article-title":"Reirradiation of locally recurrent prostate cancer with volumetric modulated arc therapy","volume":"104","author":"D'Agostino","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0037","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.prro.2015.04.009","article-title":"High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment","volume":"5","author":"Fuller","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0038","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2019.10.014","article-title":"Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: Efficacy and toxicity of HDR-like SBRT","volume":"106","author":"Fuller","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1259\/bjro.20180027","article-title":"Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group","volume":"1","author":"Scher","year":"2019","journal-title":"BJR|Open"},{"key":"10.1016\/j.prro.2023.05.007_bib0040","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102176","article-title":"Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"95","author":"Munoz","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.prro.2023.05.007_bib0042","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0043","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0044","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0045","unstructured":"Pasquier D, Lacornerie T, Supiot S, et al. The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: Phase 1 results from the GETUG-AFU 31 study. Eur Urol Oncol., in press."},{"issue":"suppl 3","key":"10.1016\/j.prro.2023.05.007_bib0046","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3171\/jns.2000.93.supplement_3.0219","article-title":"A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note","volume":"93","author":"Paddick","year":"2000","journal-title":"J Neurosurg"},{"issue":"suppl 105","key":"10.1016\/j.prro.2023.05.007_bib0047","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3171\/sup.2006.105.7.194","article-title":"A simple dose gradient measurement tool to complement the conformity index","author":"Paddick","year":"2006","journal-title":"J Neurosurg"},{"key":"10.1016\/j.prro.2023.05.007_bib0048","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/0360-3016(93)90548-A","article-title":"Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines","volume":"27","author":"Shaw","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi Consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.prro.2023.05.007_bib0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681448","article-title":"Salvage reirradiation options for locally recurrent prostate cancer: A systematic review","volume":"11","author":"Zhong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phro.2021.03.002","article-title":"Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer","volume":"18","author":"Yoshimura","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0053","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2014.01.042","article-title":"Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions","volume":"89","author":"Murray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0054","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00432-020-03297-5","article-title":"PROLAPSE: Survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: Results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"146","author":"Zerini","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0055","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2023.05.007_bib0056","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2023.05.007_bib0057","first-page":"96","article-title":"Imaging of prostate cancer with PET\/CT using 18F-fluorocholine","volume":"5","author":"Vali","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2023.05.007_bib0058","first-page":"62","article-title":"Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience","volume":"92","author":"Augugliaro","year":"2021","journal-title":"Phys Medica Eur J Med Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0059","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1259\/bjr.20170021","article-title":"Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments","volume":"90","author":"Ciardo","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2023.05.007_bib0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5306\/wjco.v8.i4.305","article-title":"Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know","volume":"8","author":"Cou\u00f1ago","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0061","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00066-023-02043-3","article-title":"Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: Toxicity and outcomes","volume":"199","author":"Cozzi","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2023.05.007_bib0062","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0063","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1259\/bjr.20190845","article-title":"A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy","volume":"93","author":"Wang","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2023.05.007_bib0064","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2018.09.039","article-title":"A prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology\/RTOG-0526)","volume":"103","author":"Crook","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0065","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage low dose rate prostate brachytherapy: Clinical outcomes of a phase II trial for local recurrence after external beam radiotherapy (NRG\/RTOG -0526)","volume":"112","author":"Crook","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.007_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858740","article-title":"1.5T MR-guided daily adaptive stereotactic body radiotherapy for prostate re-irradiation: A preliminary report of toxicity and clinical outcomes","volume":"12","author":"Cuccia","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2023.05.007_bib0067","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers14081943","article-title":"Magnetic resonance-guided reirradiation for local recurrence within the prostate or in the prostate bed: One-year clinical results of a prospective registry study","volume":"14","author":"Michalet","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prro.2023.05.007_bib0068","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00066-020-01628-6","article-title":"Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer","volume":"196","author":"Cuccia","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2023.05.007_bib0069","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4149\/neo_2020_200622N651","article-title":"Partial prostate re-irradiation for the treatment of isolated local recurrence of prostate cancer in patients previously treated with primary external beam radiotherapy: Short-term results of a monocentric study","volume":"68","author":"Matrone","year":"2021","journal-title":"Neoplasma"}],"updated-by":[{"DOI":"10.1016\/j.prro.2024.03.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T19:57:57Z","timestamp":1714593477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850023001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1879850023001637"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2023.05.007","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievable Dosimetric Constraints in Stereotactic Reirradiation for Recurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2023.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}